NEW YORK, March 10 (Reuters) - Dendreon Corp (DNDN.O) said it received U.S. regulatory approval to quadruple the manufacturing capacity for prostate cancer vaccine Provenge, allowing it to significantly increase availability of the drug to meet pent up demand.
